Oligopeptide-1 vs Nonapeptide-1
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: sh-Oligopeptide-1, rh-Oligopeptide-1
sh-Oligopeptide-1 is the cosmetic ingredient name for recombinant human epidermal growth factor (EGF), a 53-amino-acid protein your skin uses to tell cells to divide and repair. It shows up in 'EGF serums' aimed at wrinkles, texture and post-procedure recovery. It is a cosmetic ingredient in skincare, not an FDA-approved drug for skin aging, and while there are a fair number of small human studies, very few are properly controlled.
Also: Melanostatine 5, Melanostatine-5
Nonapeptide-1, sold as Melanostatine 5, is a nine-amino-acid synthetic peptide built to block alpha-MSH, the hormone that tells pigment cells to make melanin. It goes into brightening and dark-spot products as a gentler alternative to harsh lighteners. It is a cosmetic ingredient, not an FDA-approved drug, and there is no independent peer-reviewed clinical trial of it on its own.
Key Comparison Insights
- Both peptides belong to the Skin & Hair category, suggesting similar primary applications.
- Oligopeptide-1 has stronger research evidence (Human Trials) compared to Nonapeptide-1 (Limited Research).
Detailed Comparison
| Attribute | Oligopeptide-1 | Nonapeptide-1 |
|---|---|---|
| Category | Skin & Hair | Skin & Hair |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | EGF binds the EGF receptor on keratinocytes and fibroblasts and switches on growth and repair signaling: cell division, migration, and production of matrix proteins. That is why it has been studied for wound healing, and why cosmetic brands use it to support skin renewal. Two practical problems: EGF is a fairly large protein, so getting it through intact skin is hard (which is why many studies pair it with microneedling or lasers), and it is fragile, so how much stays active in a jar at room temperature is a fair question. The same growth-promoting signal is also the source of the safety debate: EGF receptor signaling drives several cancers, so the concern is not that EGF causes cancer, but whether it could encourage abnormal cells that are already there. | When skin is hit by UV, it releases alpha-MSH, which binds the MC1R receptor on melanocytes and switches on tyrosinase, the enzyme that makes melanin. Nonapeptide-1 is designed to sit in that receptor without switching it on, a competitive antagonist, so less of the tanning and pigment signal gets through. In cell studies it binds MC1R with high affinity and blocks alpha-MSH-driven melanosome dispersion at nanomolar levels, and it lowered tyrosinase and related pigment genes in human melanocytes. It is essentially the opposite of melanotan I and afamelanotide, which activate the same receptor to darken skin. The big unknown, as with most cosmetic peptides, is how much reaches melanocytes through intact skin. |
| Common Dosing | Low parts-per-million concentration in a serum Once or twice daily | Low percentage in a brightening serum Once or twice daily |
| Administration | Topical (serums, ampoules, creams); sometimes combined with microneedling in clinic | Topical (serums, creams) |
| Typical Duration | Studies typically ran 4 to 12 weeks | Brightening claims are usually judged over 8 to 12 weeks; ongoing use |
| Best Time to Take | Evening skincare routine, or right after an in-clinic procedure | Morning (under sunscreen) and/or evening |
Possible Side Effects May vary by individual |
|
|
| Research Summary | A 2021 systematic review in the Journal of Cutaneous and Aesthetic Surgery (Miller-Kobisher and colleagues) found 49 articles on rhEGF for skin, including 23 aesthetic studies. Most reported less wrinkling, better hydration and elasticity, and the strongest data were for pigmentation after lasers and melasma. But the authors admit many trials were uncontrolled or not randomized, samples were often 8 to 40 people, and they called for proper controlled trials. Adverse effects were mild and short-lived. The review did not address cancer risk at all, which is a real gap. Several of the better-known growth-factor trials tested multi-factor mixtures, not EGF alone. On safety: there is no human evidence that cosmetic EGF causes skin cancer, and in vitro tests of growth-factor cosmetics on melanoma cells were reassuring, but long-term studies in healthy skin do not exist. Sensible caution: people with a history of skin cancer, many atypical moles, or active psoriasis should talk to a dermatologist before using it. Bottom line: plausible and widely used, modest and mostly low-quality efficacy data, and an unresolved theoretical safety question. | The evidence is thin and mostly commercial. Receptor binding and anti-pigment effects come from cell work and supplier data sheets. In a 2022 paper in Postepy Dermatologii i Alergologii (Chen and colleagues), nonapeptide-1 was used as a reference MC1R blocker in UVA-exposed human melanocytes and keratinocytes, where it reduced pigment pathway activity, but the study's focus was tea polyphenols, not the peptide. Ingredient databases describe the human data as small and manufacturer-generated. You will see claims online of a 12-week, 40-person trial where a cream with this peptide matched 4 percent hydroquinone for melasma, but we could not find a published, citable version, and even then it was a multi-ingredient cream. Fair summary: a well-designed molecule with a clear mechanism in cells, and very little real-world proof. Sunscreen still does more for dark spots than any single brightening peptide. |
Frequently Asked Questions: Oligopeptide-1 vs Nonapeptide-1
What is the difference between Oligopeptide-1 and Nonapeptide-1?
Oligopeptide-1 is a skin & hair peptide that sh-oligopeptide-1 is the cosmetic ingredient name for recombinant human epidermal growth factor (egf), a 53-amino-acid protein your skin uses to tell cells to divide and repair. it shows up in 'egf serums' aimed at wrinkles, texture and post-procedure recovery. it is a cosmetic ingredient in skincare, not an fda-approved drug for skin aging, and while there are a fair number of small human studies, very few are properly controlled. Nonapeptide-1 is a skin & hair peptide that nonapeptide-1, sold as melanostatine 5, is a nine-amino-acid synthetic peptide built to block alpha-msh, the hormone that tells pigment cells to make melanin. it goes into brightening and dark-spot products as a gentler alternative to harsh lighteners. it is a cosmetic ingredient, not an fda-approved drug, and there is no independent peer-reviewed clinical trial of it on its own. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Oligopeptide-1 or Nonapeptide-1?
Neither is universally "better" - the choice depends on your specific goals. Oligopeptide-1 is typically used for skin & hair purposes, while Nonapeptide-1 is used for skin & hair. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Oligopeptide-1 and Nonapeptide-1 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Oligopeptide-1 and Nonapeptide-1 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.